Article info
PDFResearch ethics
Paper
The EU Clinical Trials Regulation: key priorities, purposes and aims and the implications for public health
- Correspondence to Dr Mark L Flear, School of Law, Queen's University Belfast, 27-30 University Square, Belfast, BT7 1NN, UK; m.flear{at}qub.ac.uk
Citation
The EU Clinical Trials Regulation: key priorities, purposes and aims and the implications for public health
Publication history
- Received January 4, 2016
- Accepted January 6, 2016
- First published February 1, 2016.
Online issue publication
February 09, 2017
Article Versions
- Previous version (27 April 2016).
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs
- News from the European Union
- Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution
- Compliance of e-cigarette refill liquids with regulations on labelling, packaging and technical design characteristics in nine European member states
- Current models, challenges and best practices for work conducted between European academic cooperative groups and industry
- Health impact assessment: assessing opportunities and barriers to intersectoral health improvement in an expanded European Union
- Simplified consent in cluster randomised trials: the new EU Clinical Trials Regulation does not provide sufficient guidance
- Regulating the advertising of genetic tests in Europe: a balancing act
- Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients
- Running an international paediatric non-commercial clinical trial